SUPERVISORY GENERAL ATTORNEY 21-EX-10997082-TS 01/13/2021 to 01/27/2021 $138,191 to $236,167 Washington, DC https://go.usa.gov/xAPe3 The Division of Enforcement investigates possible violations of securities laws, recommends Commission action when appropriate, either in a federal court or before an administrative law judge, and negotiates settlements. Responsibilities The Office of Market Intelligence is responsible for a variety of intelligence, analytic, and data and technology programs and activities to identify fraud, misconduct, market practices and other activities that constitute securities law violations and pose potential risks to investors. OMI intakes, analyzes, and evaluates thousands of tips, complaints, and referrals (TCRs) and other reports, information, data, and intelligence that the SEC receives each year, and develops and refers leads to agency staff for potential investigation or other response. If selected, you will serve as a Supervisory General Attorney (Branch C
SEC Charges Biotech Company and CEO with Fraud Concerning COVID-19 Blood Testing Device
Washington, D.C. (Newsfile Corp. - December 18, 2020) - The Securities and Exchange Commission today announced charges against California-based biotechnology company Decision Diagnostics Corp. and its CEO, Keith Berman, with making false and misleading claims in numerous press releases that the company had developed a working, break-through technology that could accurately detect Covid-19 through a quick blood test. The SEC temporarily suspended trading in Decision Diagnostics securities on April 23, 2020.
The SEC s complaint alleges that Decision Diagnostics and Berman seized upon the global pandemic through a series of press releases that falsely claimed Decision Diagnostics had developed a finger prick blood test that could detect Covid-19 in less than a minute. According to the complaint, from March 2020 to at least June 2020, Decision Diagnostics and Berman made false and misleading stat
FOR IMMEDIATE RELEASE Washington D.C., Dec. 18, 2020
The Securities and Exchange Commission today announced charges against California-based biotechnology company Decision Diagnostics Corp. and its CEO, Keith Berman, with making false and misleading claims in numerous press releases that the company had developed a working, break-through technology that could accurately detect Covid-19 through a quick blood test. The SEC temporarily suspended trading in Decision Diagnostics securities on April 23, 2020.
The SEC s complaint alleges that Decision Diagnostics and Berman seized upon the global pandemic through a series of press releases that falsely claimed Decision Diagnostics had developed a finger prick blood test that could detect Covid-19 in less than a minute. According to the complaint, from March 2020 to at least June 2020, Decision Diagnostics and Berman made false and misleading statements about the existence of Decision Diagnostics Covid-19 device an